WallStreetZenWallStreetZen

NYSE: RDY
Dr Reddys Laboratories Ltd Stock

$53.09-0.74 (-1.37%)
Updated Feb 3, 2023
RDY Price
$53.09
Fair Value Price
N/A
Market Cap
$8.84B
52 Week Low
$47.88
52 Week High
$58.38
P/E
29.3x
P/B
3.64x
P/S
3.29x
PEG
1.15x
Dividend Yield
1.46%
Revenue
$2.73B
Earnings
$309.29M
Gross Margin
53.1%
Operating Margin
15.51%
Profit Margin
11%
Debt to Equity
0.54
Operating Cash Flow
$466M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

RDY Overview

Dr. Reddy's Laboratories Limited manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary pharmaceutical products. It's generic products are indicated for the treatment of gastrointestinal disorders, various cancers, cardiovascular diseases, pain, central nervous system disorders, infectious diseases, and pediatric diseases. Its pipeline includes New Chemical Entities that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. Dr. Reddy's Laboratories was incorporated in 1984 and is headquartered in Hyderabad, India.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RDY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RDY ($53.09) is trading above its intrinsic value of $28.55, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RDY is poor value based on its earnings relative to its share price (29.3x), compared to the US market average (15.09x)
P/E vs Market Valuation
RDY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more RDY due diligence checks available for Premium users.

Be the first to know about important RDY news, forecast changes, insider trades & much more!

RDY News

Valuation

RDY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
29.3x
Industry
18.24x
Market
15.09x
RDY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RDY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

RDY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.64x
Industry
1.9x
RDY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RDY price to earnings growth (PEG)

For valuing profitable companies with growth potential
RDY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

RDY's financial health

Profit margin

Revenue
$2.8B
Net Income
$309.3M
Profit Margin
11%
RDY's Earnings (EBIT) of $424.18M... subscribe to Premium to read more.
Interest Coverage Financials
RDY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.8B
Liabilities
$1.3B
Debt to equity
0.54
RDY's short-term assets ($2.32B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDY's short-term assets ($2.32B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RDY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$466.5M
Investing
-$346.3M
Financing
-$31.8M
RDY's operating cash flow ($453.38M)... subscribe to Premium to read more.
Debt Coverage Financials

RDY vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
RDY$8.84B-1.37%29.30x3.64x
CTLT$10.09B-1.04%23.85x2.15x
ELAN$6.58B-4.87%-57.79x0.98x
TEVA$11.95B+0.47%-9.28x1.36x
PRGO$5.01B+0.40%-46.50x1.09x

Dr Reddys Laboratories Stock FAQ

What is Dr Reddys Laboratories's quote symbol?

NYSE: RDY) Dr Reddys Laboratories trades on the NYSE under the ticker symbol RDY. Dr Reddys Laboratories stock quotes can also be displayed as NYSE: RDY.

If you're new to stock investing, here's how to buy Dr Reddys Laboratories stock.

What is the 52 week high and low for Dr Reddys Laboratories (NYSE: RDY)?

(NYSE: RDY) Dr Reddys Laboratories's 52-week high was $58.38, and its 52-week low was $47.88. It is currently -9.06% from its 52-week high and 10.88% from its 52-week low.

How much is Dr Reddys Laboratories stock worth today?

(NYSE: RDY) Dr Reddys Laboratories currently has 166,425,849 outstanding shares. With Dr Reddys Laboratories stock trading at $53.09 per share, the total value of Dr Reddys Laboratories stock (market capitalization) is $8.84B.

Dr Reddys Laboratories stock was originally listed at a price of $5.05 in Apr 11, 2001. If you had invested in Dr Reddys Laboratories stock at $5.05, your return over the last 21 years would have been 951.29%, for an annualized return of 11.85% (not including any dividends or dividend reinvestments).

How much is Dr Reddys Laboratories's stock price per share?

(NYSE: RDY) Dr Reddys Laboratories stock price per share is $53.09 today (as of Feb 3, 2023).

What is Dr Reddys Laboratories's Market Cap?

(NYSE: RDY) Dr Reddys Laboratories's market cap is $8.84B, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Dr Reddys Laboratories's market cap is calculated by multiplying RDY's current stock price of $53.09 by RDY's total outstanding shares of 166,425,849.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.